# A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis

> **NCT07364448** · PHASE2 · RECRUITING · sponsor: **Beijing Continent Pharmaceutical Co, Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis B With Hepatic Fibrosis

## Interventions

- **DRUG:** Hydronidone capsules

## Key facts

- **NCT ID:** NCT07364448
- **Lead sponsor:** Beijing Continent Pharmaceutical Co, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-12
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07364448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07364448, "A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07364448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*